--- title: "Canton Hathaway LLC Has $1.05 Million Stock Holdings in Eli Lilly and Company $LLY" type: "News" locale: "en" url: "https://longbridge.com/en/news/296450496.md" description: "Canton Hathaway LLC reduced its Eli Lilly (LLY) holdings by 61.6% in Q2, leaving $1.05 million in stock. Meanwhile, several other institutions increased their stakes. Analysts remain bullish, with JPMorgan, Leerink, Sanford C. Bernstein, Guggenheim, and Morgan Stanley raising price targets or maintaining positive ratings. Key drivers include strong Q2 earnings, robust GLP-1 sales growth, and pipeline advancements." datetime: "2026-08-20T07:30:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296450496.md) - [en](https://longbridge.com/en/news/296450496.md) - [zh-HK](https://longbridge.com/zh-HK/news/296450496.md) --- # Canton Hathaway LLC Has $1.05 Million Stock Holdings in Eli Lilly and Company $LLY Canton Hathaway LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 61.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 873 shares of the company's stock after selling 1,400 shares during the period. Canton Hathaway LLC's holdings in Eli Lilly and Company were worth $1,047,000 at the end of the most recent reporting period. Get **Eli Lilly and Company** alerts: - The FTC Is Suing Hims & Hers Health—Here's Why Investors Shouldn't Panic A number of other institutional investors and hedge funds have also modified their holdings of LLY. Osbon Capital Management LLC bought a new stake in Eli Lilly and Company during the 4th quarter valued at approximately $25,000. Basso Capital Management L.P. bought a new position in Eli Lilly and Company during the 4th quarter valued at about $30,000. E Fund Management Hong Kong Co. Ltd. boosted its stake in Eli Lilly and Company by 342.9% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company's stock worth $32,000 after purchasing an additional 24 shares in the last quarter. New England Capital Financial Advisors LLC lifted its position in shares of Eli Lilly and Company by 142.9% during the fourth quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company's stock worth $37,000 after purchasing an additional 20 shares in the last quarter. Finally, Maseco LLP boosted its holdings in Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company's stock valued at $31,000 after acquiring an additional 28 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds. ## Wall Street Analyst Weigh In Several brokerages have commented on LLY. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an "overweight" rating in a research report on Tuesday, July 7th. Leerink Partners raised their price objective on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an "outperform" rating in a report on Thursday, June 25th. Sanford C. Bernstein boosted their target price on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an "outperform" rating in a research note on Tuesday, July 14th. Guggenheim increased their price target on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a "buy" rating in a research report on Monday, July 13th. Finally, Morgan Stanley reiterated an "overweight" rating and issued a $1,419.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $1,292.18. - As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner **Get Our Latest Research Report on Eli Lilly and Company** ## Key Stories Impacting Eli Lilly and Company Here are the key news stories impacting Eli Lilly and Company this week: - Positive Sentiment: **Obesity-drug momentum remains the primary catalyst.** Lilly’s Zepbound sales reportedly rose 46%, while its broader GLP-1 portfolio outperformed Novo Nordisk’s in the latest quarter. Investors are also focused on Lilly’s potential oral obesity treatments and retatrutide, which could expand the company’s addressable market beyond weekly injections. How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's? - Positive Sentiment: **Fundamentals support the bullish narrative.** Lilly’s latest quarter exceeded consensus estimates, with earnings per share of $8.38 versus $6.40 expected and revenue of $22.97 billion versus $20.82 billion expected. Revenue increased 47.7% year over year, and fiscal 2026 earnings guidance remains strong. Could Eli Lilly Be Worth More Than SpaceX by the End of 2026? - Positive Sentiment: **Pipeline and business-development activity is broadening.** Lilly is advancing oral and metabolic-health candidates, completing early-stage work on lepodisiran and LY4086940, and studying a new LY4065967 formulation. Partnerships with OmniAb and AlzeCure add potential neuroscience and central-nervous-system opportunities. Eli Lilly Expands Neuroscience Reach With New Drug Deals - Neutral Sentiment: **Market conditions provided additional support.** Lower Treasury yields and gains across major biotech and pharmaceutical stocks improved the sector backdrop, although these factors are not specific to Lilly. Dow Jones Futures: S&P 500, Nasdaq Rise on Treasury Move - Negative Sentiment: **Valuation and competition are key risks.** With a market capitalization above $1 trillion and a premium earnings multiple, Lilly must continue delivering strong growth. Novo Nordisk and potential entrants such as Pfizer remain competitors in oral and injectable obesity treatments. - Negative Sentiment: **An insider sale creates a limited headwind.** EVP Patrik Jonsson sold 6,500 shares for approximately $7.6 million under a pre-arranged Rule 10b5-1 plan. Because the sale was scheduled in advance, it is a weaker bearish signal. SEC Insider Transaction Filing ## Eli Lilly and Company Stock Performance - 3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend Eli Lilly and Company stock opened at $1,280.62 on Thursday. The stock has a market cap of $1.21 trillion, a PE ratio of 42.97, a P/E/G ratio of 1.45 and a beta of 0.51. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The business's 50-day moving average price is $1,176.04 and its two-hundred day moving average price is $1,056.96. Eli Lilly and Company has a 12-month low of $685.15 and a 12-month high of $1,292.65. Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter in the prior year, the firm earned $6.31 EPS. The firm's revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, analysts expect that Eli Lilly and Company will post 36.35 earnings per share for the current fiscal year. ## Eli Lilly and Company Dividend Announcement The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company's dividend payout ratio is currently 23.22%. ## Insider Buying and Selling at Eli Lilly and Company In related news, EVP Patrik Jonsson sold 6,500 shares of the company's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. The trade was a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is currently owned by company insiders. ## Eli Lilly and Company Company Profile (Free Report) Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A. ## Featured Stories - Five stocks we like better than Eli Lilly and Company - Bloom Energy’s AI Surge Meets a Valuation Reality Check - Target Is Winning Shoppers Back—Can the Rally Reach $180? - IonQ’s Space Contract Points to a New Frontier for Quantum Investors - Is Apple’s AI Strategy Smarter Than Skeptics Think? _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Eli Lilly and Company Right Now? Before you consider Eli Lilly and Company, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list. While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) - [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md) - [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md) - [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md) - [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md) - [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md) - [JPM.US](https://longbridge.com/en/quote/JPM.US.md) - [MS.US](https://longbridge.com/en/quote/MS.US.md) - [NVO.US](https://longbridge.com/en/quote/NVO.US.md) - [OABI.US](https://longbridge.com/en/quote/OABI.US.md) - [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md) - [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md) - [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md) - [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md) - [8634.JP](https://longbridge.com/en/quote/8634.JP.md) - [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md) - [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md) - [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md) - [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md) - [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md) - [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md) - [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md) - [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md) - [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md) - [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md) - [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md) - [OABIW.US](https://longbridge.com/en/quote/OABIW.US.md) ## Related News & Research - [Eli Lilly and Company $LLY is Donaldson Capital Management LLC's 7th Largest Position](https://longbridge.com/en/news/296452149.md) - [Elyxium Wealth LLC Has $7.30 Million Position in Eli Lilly and Company $LLY](https://longbridge.com/en/news/296017075.md) - [Principal Financial Group Inc. Buys 29,020 Shares of Eli Lilly and Company $LLY](https://longbridge.com/en/news/296204327.md) - [Why Is Omniab Stock Rallying After Eli Lilly Deal?](https://longbridge.com/en/news/296113651.md) - [How Eli Lilly’s Global Vault CRM Rollout At Veeva Systems (VEEV) Has Changed Its Investment Story](https://longbridge.com/en/news/296430987.md)